Logo

Sorrento Initiates Enrollment in P-II MSC-COV-202BR Study for the Treatment of Acute Respiratory Distress due to COVID-19 in Brazil

Share this

Sorrento Initiates Enrollment in P-II MSC-COV-202BR Study for the Treatment of Acute Respiratory Distress due to COVID-19 in Brazil

Shots:

  • The first patient has been enrolled at the first site in P-II MSC-COV-202BR efficacy study evaluates COVI-MSC vs PBO in 100 patients with COVID-19-induced ARD or ARDS in Brazil
  • The primary objective of the study is to evaluate the efficacy of COVI-MSCs in patients with COVID-19-induced ARD or ARDS
  • Additionally- the company plans to start the enrollment for two additional P-III studies with COVI-MSC across multiple sites in the US & Brazil

| Ref: Sorrento | Image: City Biz

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions